Evidence Feed - LARVOL VERI

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	ciltacabtagene autoleucel Sensitive: A1 - Approval Legend Biotech - Today (New A1) ciltacabtagene autoleucel Sensitive : A1 Legend Biotech -	ciltacabtagene autoleucel Sensitive: A1 - Approval Legend Biotech - Today ciltacabtagene autoleucel Sensitive : A1 Legend Biotech - Today - (New A1)
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 2 weeks (New A1) pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 2wk	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 2 weeks pembrolizumab Sensitive : A1 Merck (MSD) Press Release - 2 weeks - (New A1)
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today (New A1) pembrolizumab Sensitive : A1 Merck (MSD) Press Release -	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today pembrolizumab Sensitive : A1 Merck (MSD) Press Release - Today - (New A1)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today (New A1) pembrolizumab Sensitive : A1 Merck (MSD) Press Release -	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today pembrolizumab Sensitive : A1 Merck (MSD) Press Release - Today - (New A1)
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	pembrolizumab + bevacizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today (New A1) pembrolizumab + bevacizumab Sensitive : A1 Merck (MSD) Press Release -	pembrolizumab + bevacizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today pembrolizumab + bevacizumab Sensitive : A1 Merck (MSD) Press Release - Today - (New A1)
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today (New A1) pembrolizumab Sensitive : A1 Merck (MSD) Press Release -	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - Today pembrolizumab Sensitive : A1 Merck (MSD) Press Release - Today - (New A1)
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	valemetostat Sensitive: A1 - Approval Daiichi Sankyo Press Release - 1 day (New A1) valemetostat Sensitive : A1 Daiichi Sankyo Press Release - 1d	valemetostat Sensitive: A1 - Approval Daiichi Sankyo Press Release - 1 day valemetostat Sensitive : A1 Daiichi Sankyo Press Release - 1 day - (New A1)
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval Pharmamar Press Release - 4 days (New A1) lurbinectedin Sensitive : A1 Pharmamar Press Release - 4d	lurbinectedin Sensitive: A1 - Approval Pharmamar Press Release - 4 days lurbinectedin Sensitive : A1 Pharmamar Press Release - 4 days - (New A1)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval NICE - 4 days (New A2) palbociclib Sensitive : A1 NICE - 4d	palbociclib Sensitive: A1 - Approval NICE - 4 days palbociclib Sensitive : A1 NICE - 4 days - (New A2)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval ASCO.org - 4 days (New A2) rucaparib Sensitive : A1 ASCO.org - 4d	rucaparib Sensitive: A1 - Approval ASCO.org - 4 days rucaparib Sensitive : A1 ASCO.org - 4 days - (New A2)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	rucaparib Sensitive: A1 - Approval ASCO.org - 4 days (New A2) rucaparib Sensitive : A1 ASCO.org - 4d	rucaparib Sensitive: A1 - Approval ASCO.org - 4 days rucaparib Sensitive : A1 ASCO.org - 4 days - (New A2)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval ASCO.org - 4 days (New A2) olaparib Sensitive : A1 ASCO.org - 4d	olaparib Sensitive: A1 - Approval ASCO.org - 4 days olaparib Sensitive : A1 ASCO.org - 4 days - (New A2)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib Sensitive: A1 - Approval ASCO.org - 4 days (New A2) olaparib Sensitive : A1 ASCO.org - 4d	olaparib Sensitive: A1 - Approval ASCO.org - 4 days olaparib Sensitive : A1 ASCO.org - 4 days - (New A2)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval ASCO.org - 4 days (New A2) niraparib Sensitive : A1 ASCO.org - 4d	niraparib Sensitive: A1 - Approval ASCO.org - 4 days niraparib Sensitive : A1 ASCO.org - 4 days - (New A2)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	niraparib Sensitive: A1 - Approval ASCO.org - 4 days (New A2) niraparib Sensitive : A1 ASCO.org - 4d	niraparib Sensitive: A1 - Approval ASCO.org - 4 days niraparib Sensitive : A1 ASCO.org - 4 days - (New A2)
HRD	Ovarian Cancer	HRD	Ovarian Cancer	niraparib Sensitive: A1 - Approval ASCO.org - 4 days (New A2) niraparib Sensitive : A1 ASCO.org - 4d	niraparib Sensitive: A1 - Approval ASCO.org - 4 days niraparib Sensitive : A1 ASCO.org - 4 days - (New A2)
HRD	Ovarian Cancer	HRD	Ovarian Cancer	rucaparib Sensitive: A2 - Guideline ASCO.org - 4 days (New A2) rucaparib Sensitive : A2 ASCO.org - 4d	rucaparib Sensitive: A2 - Guideline ASCO.org - 4 days rucaparib Sensitive : A2 ASCO.org - 4 days - (New A2)
EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	EGFR T263P + EGFR L858R + MET amplification	Non Small Cell Lung Cancer	erlotinib + capmatinib Sensitive: C4 – Case Studies Front Oncol - 4 days (New C4) erlotinib + capmatinib Sensitive : C4 Front Oncol - 4d	erlotinib + capmatinib Sensitive: C4 – Case Studies Front Oncol - 4 days erlotinib + capmatinib Sensitive : C4 Front Oncol - 4 days - (New C4)
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline PMLive - 5 days (New A2) pembrolizumab Sensitive : A2 PMLive - 5d	pembrolizumab Sensitive: A2 - Guideline PMLive - 5 days pembrolizumab Sensitive : A2 PMLive - 5 days - (New A2)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	ivosidenib Sensitive: A1 - Approval SOHO 2022 - 6 days (New C3) ivosidenib Sensitive : A1 SOHO 2022 - 6d	ivosidenib Sensitive: A1 - Approval SOHO 2022 - 6 days ivosidenib Sensitive : A1 SOHO 2022 - 6 days - (New C3)
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: A2 - Guideline SOHO 2022 - 6 days (New B) zanubrutinib Sensitive : A2 SOHO 2022 - 6d	zanubrutinib Sensitive: A2 - Guideline SOHO 2022 - 6 days zanubrutinib Sensitive : A2 SOHO 2022 - 6 days - (New B)
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: A2 - Guideline SOHO 2022 - 6 days (New B) zanubrutinib Sensitive : A2 SOHO 2022 - 6d	zanubrutinib Sensitive: A2 - Guideline SOHO 2022 - 6 days zanubrutinib Sensitive : A2 SOHO 2022 - 6 days - (New B)
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days (New C3) Immunotherapy Sensitive : B Onco Targets Ther - 6d	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days Immunotherapy Sensitive : B Onco Targets Ther - 6 days - (New C3)
TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	TP53 mutation + KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days (New C3) Immunotherapy Sensitive : B Onco Targets Ther - 6d	Immunotherapy Sensitive: B - Late Trials Onco Targets Ther - 6 days Immunotherapy Sensitive : B Onco Targets Ther - 6 days - (New C3)
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	zanubrutinib Sensitive: B - Late Trials SOHO 2022 - 6 days (New B) zanubrutinib Sensitive : B SOHO 2022 - 6d	zanubrutinib Sensitive: B - Late Trials SOHO 2022 - 6 days zanubrutinib Sensitive : B SOHO 2022 - 6 days - (New B)
Chr del(11q)	Small Lymphocytic Lymphoma	Chr del(11q)	Small Lymphocytic Lymphoma	zanubrutinib Sensitive: B - Late Trials SOHO 2022 - 6 days (New B) zanubrutinib Sensitive : B SOHO 2022 - 6d	zanubrutinib Sensitive: B - Late Trials SOHO 2022 - 6 days zanubrutinib Sensitive : B SOHO 2022 - 6 days - (New B)
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials SOHO 2022 - 6 days (New B) zanubrutinib Sensitive : B SOHO 2022 - 6d	zanubrutinib Sensitive: B - Late Trials SOHO 2022 - 6 days zanubrutinib Sensitive : B SOHO 2022 - 6 days - (New B)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval SOHO 2022 - 6 days (New C3) gilteritinib Sensitive : A1 SOHO 2022 - 6d	gilteritinib Sensitive: A1 - Approval SOHO 2022 - 6 days gilteritinib Sensitive : A1 SOHO 2022 - 6 days - (New C3)
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	enasidenib Sensitive: A1 - Approval SOHO 2022 - 6 days (New C3) enasidenib Sensitive : A1 SOHO 2022 - 6d	enasidenib Sensitive: A1 - Approval SOHO 2022 - 6 days enasidenib Sensitive : A1 SOHO 2022 - 6 days - (New C3)
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	nilotinib Sensitive: A1 - Approval SOHO 2022 - 6 days (New C4) nilotinib Sensitive : A1 SOHO 2022 - 6d	nilotinib Sensitive: A1 - Approval SOHO 2022 - 6 days nilotinib Sensitive : A1 SOHO 2022 - 6 days - (New C4)
Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	lenalidomide Sensitive: A1 - Approval SOHO 2022 - 6 days (New C3) lenalidomide Sensitive : A1 SOHO 2022 - 6d	lenalidomide Sensitive: A1 - Approval SOHO 2022 - 6 days lenalidomide Sensitive : A1 SOHO 2022 - 6 days - (New C3)
RET fusion	Solid Tumor	RET fusion	Solid Tumor	selpercatinib Sensitive: A1 - Approval Eli Lilly Press Release - 6 days (New A1) selpercatinib Sensitive : A1 Eli Lilly Press Release - 6d	selpercatinib Sensitive: A1 - Approval Eli Lilly Press Release - 6 days selpercatinib Sensitive : A1 Eli Lilly Press Release - 6 days - (New A1)
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline SOHO 2022 - 6 days (New C3) venetoclax Sensitive : A2 SOHO 2022 - 6d	venetoclax Sensitive: A2 - Guideline SOHO 2022 - 6 days venetoclax Sensitive : A2 SOHO 2022 - 6 days - (New C3)
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: B - Late Trials SOHO 2022 - 6 days (New C3) venetoclax Resistant : B SOHO 2022 - 6d	venetoclax Resistant: B - Late Trials SOHO 2022 - 6 days venetoclax Resistant : B SOHO 2022 - 6 days - (New C3)
TP53 mutation	Chronic Myelomonocytic Leukemia	TP53 mutation	Chronic Myelomonocytic Leukemia	venetoclax Sensitive: C1 - Off-label SOHO 2022 - 6 days (New C3) venetoclax Sensitive : C1 SOHO 2022 - 6d	venetoclax Sensitive: C1 - Off-label SOHO 2022 - 6 days venetoclax Sensitive : C1 SOHO 2022 - 6 days - (New C3)
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	venetoclax Sensitive: C2 – Inclusion Criteria SOHO 2022 - 6 days (New C3) venetoclax Sensitive : C2 SOHO 2022 - 6d	venetoclax Sensitive: C2 – Inclusion Criteria SOHO 2022 - 6 days venetoclax Sensitive : C2 SOHO 2022 - 6 days - (New C3)
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C2 – Inclusion Criteria SOHO 2022 - 6 days (New C3) MEN1703 Sensitive : C2 SOHO 2022 - 6d	MEN1703 Sensitive: C2 – Inclusion Criteria SOHO 2022 - 6 days MEN1703 Sensitive : C2 SOHO 2022 - 6 days - (New C3)
CD20 expression	B Acute Lymphoblastic Leukemia	CD20 expression	B Acute Lymphoblastic Leukemia	rituximab Sensitive: C3 – Early Trials SOHO 2022 - 6 days (New C3) rituximab Sensitive : C3 SOHO 2022 - 6d	rituximab Sensitive: C3 – Early Trials SOHO 2022 - 6 days rituximab Sensitive : C3 SOHO 2022 - 6 days - (New C3)
IDH1 mutation	Myelodysplastic Syndrome	IDH1 mutation	Myelodysplastic Syndrome	venetoclax + ivosidenib Sensitive: C3 – Early Trials SOHO 2022 - 6 days (New C3) venetoclax + ivosidenib Sensitive : C3 SOHO 2022 - 6d	venetoclax + ivosidenib Sensitive: C3 – Early Trials SOHO 2022 - 6 days venetoclax + ivosidenib Sensitive : C3 SOHO 2022 - 6 days - (New C3)
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	MEN1703 Sensitive: C3 – Early Trials SOHO 2022 - 6 days (New C3) MEN1703 Sensitive : C3 SOHO 2022 - 6d	MEN1703 Sensitive: C3 – Early Trials SOHO 2022 - 6 days MEN1703 Sensitive : C3 SOHO 2022 - 6 days - (New C3)
KRAS mutation + KMT2C mutation	Non Small Cell Lung Cancer	KRAS mutation + KMT2C mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Onco Targets Ther - 6 days (New C3) Immunotherapy Sensitive : C3 Onco Targets Ther - 6d	Immunotherapy Sensitive: C3 – Early Trials Onco Targets Ther - 6 days Immunotherapy Sensitive : C3 Onco Targets Ther - 6 days - (New C3)
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials SOHO 2022 - 6 days (New C3) CD30-targeted CAR-T immunotherapy Sensitive : C3 SOHO 2022 - 6d	CD30-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials SOHO 2022 - 6 days CD30-targeted CAR-T immunotherapy Sensitive : C3 SOHO 2022 - 6 days - (New C3)
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	GS-4721 Sensitive: C3 – Early Trials SOHO 2022 - 6 days (New C3) GS-4721 Sensitive : C3 SOHO 2022 - 6d	GS-4721 Sensitive: C3 – Early Trials SOHO 2022 - 6 days GS-4721 Sensitive : C3 SOHO 2022 - 6 days - (New C3)
TP53 wild-type	Myelodysplastic Syndrome	TP53 wild-type	Myelodysplastic Syndrome	GS-4721 Sensitive: C3 – Early Trials SOHO 2022 - 6 days (New C3) GS-4721 Sensitive : C3 SOHO 2022 - 6d	GS-4721 Sensitive: C3 – Early Trials SOHO 2022 - 6 days GS-4721 Sensitive : C3 SOHO 2022 - 6 days - (New C3)
STRN-ALK fusion	Lung Adenocarcinoma	STRN-ALK fusion	Lung Adenocarcinoma	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 6 days (New C4) ensartinib Sensitive : C4 Curr Oncol - 6d	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 6 days ensartinib Sensitive : C4 Curr Oncol - 6 days - (New C4)
KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies SOHO 2022 - 6 days (New C4) cytarabine + midostaurin + daunorubicin Sensitive : C4 SOHO 2022 - 6d	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies SOHO 2022 - 6 days cytarabine + midostaurin + daunorubicin Sensitive : C4 SOHO 2022 - 6 days - (New C4)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TP-0184 Sensitive: D – Preclinical SOHO 2022 - 6 days (New D) TP-0184 Sensitive : D SOHO 2022 - 6d	TP-0184 Sensitive: D – Preclinical SOHO 2022 - 6 days TP-0184 Sensitive : D SOHO 2022 - 6 days - (New D)
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week (New B) nivolumab Sensitive : A1 Int J Cancer - 1wk	nivolumab Sensitive: A1 - Approval Int J Cancer - 1 week nivolumab Sensitive : A1 Int J Cancer - 1 week - (New B)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval NCCN - 1 week (New A2) brentuximab vedotin Sensitive : A1 NCCN - 1wk	brentuximab vedotin Sensitive: A1 - Approval NCCN - 1 week brentuximab vedotin Sensitive : A1 NCCN - 1 week - (New A2)
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 1 week (New A2) zanubrutinib Sensitive : A1 BeiGene Press Release - 1wk	zanubrutinib Sensitive: A1 - Approval BeiGene Press Release - 1 week zanubrutinib Sensitive : A1 BeiGene Press Release - 1 week - (New A2)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab Sensitive: A1 - Approval NCCN - 1 week (New A2) nivolumab Sensitive : A1 NCCN - 1wk	nivolumab Sensitive: A1 - Approval NCCN - 1 week nivolumab Sensitive : A1 NCCN - 1 week - (New A2)
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week (New A1) toripalimab Sensitive : A1 GlobeNewswire - 1wk	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week toripalimab Sensitive : A1 GlobeNewswire - 1 week - (New A1)
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	rituximab/hyaluronidase Sensitive: A2 - Guideline NCCN - 1 week (New A2) rituximab / hyaluronidase Sensitive : A2 NCCN - 1wk	rituximab/hyaluronidase Sensitive: A2 - Guideline NCCN - 1 week rituximab / hyaluronidase Sensitive : A2 NCCN - 1 week - (New A2)
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	envafolimab Sensitive: B - Late Trials Tracon Pharmaceuticals Press Release - 1 week (New B) envafolimab Sensitive : B Tracon Pharmaceuticals Press Release - 1wk	envafolimab Sensitive: B - Late Trials Tracon Pharmaceuticals Press Release - 1 week envafolimab Sensitive : B Tracon Pharmaceuticals Press Release - 1 week - (New B)
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	selpercatinib Sensitive: A1 - Approval J Clin Oncol - 1 week (New C3) selpercatinib Sensitive : A1 J Clin Oncol - 1wk	selpercatinib Sensitive: A1 - Approval J Clin Oncol - 1 week selpercatinib Sensitive : A1 J Clin Oncol - 1 week - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval Cancer Cell Int - 1 week (New D) trastuzumab Sensitive : A1 Cancer Cell Int - 1wk	trastuzumab Sensitive: A1 - Approval Cancer Cell Int - 1 week trastuzumab Sensitive : A1 Cancer Cell Int - 1 week - (New D)
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week (New A1) pemigatinib Sensitive : A1 PRNewswire - 1wk	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week pemigatinib Sensitive : A1 PRNewswire - 1 week - (New A1)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week (New A1) pemigatinib Sensitive : A1 PRNewswire - 1wk	pemigatinib Sensitive: A1 - Approval PRNewswire - 1 week pemigatinib Sensitive : A1 PRNewswire - 1 week - (New A1)
PD-L1 underexpression	Melanoma	PD-L1 underexpression	Melanoma	nivolumab/relatlimab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 1 week (New A1) nivolumab / relatlimab Sensitive : A1 Bristol-Myers Squibb Press Release - 1wk	nivolumab/relatlimab Sensitive: A1 - Approval Bristol-Myers Squibb Press Release - 1 week nivolumab / relatlimab Sensitive : A1 Bristol-Myers Squibb Press Release - 1 week - (New A1)
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline Front Oncol - 1 week (New C4) pembrolizumab Sensitive : A2 Front Oncol - 1wk	pembrolizumab Sensitive: A2 - Guideline Front Oncol - 1 week pembrolizumab Sensitive : A2 Front Oncol - 1 week - (New C4)
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide Sensitive: A2 - Guideline Transl Oncol - 1 week (New D) temozolomide Sensitive : A2 Transl Oncol - 1wk	temozolomide Sensitive: A2 - Guideline Transl Oncol - 1 week temozolomide Sensitive : A2 Transl Oncol - 1 week - (New D)
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: B - Late Trials Seagen Press Release - 1 week (New B) trastuzumab + tucatinib Sensitive : B Seagen Press Release - 1wk	trastuzumab + tucatinib Sensitive: B - Late Trials Seagen Press Release - 1 week trastuzumab + tucatinib Sensitive : B Seagen Press Release - 1 week - (New B)
ALK translocation	Non Small Cell Lung Cancer	ALK translocation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria Lung Cancer - 1 week (New C3) crizotinib Sensitive : C2 Lung Cancer - 1wk	crizotinib Sensitive: C2 – Inclusion Criteria Lung Cancer - 1 week crizotinib Sensitive : C2 Lung Cancer - 1 week - (New C3)
EPHA5 mutation	Non Small Cell Lung Cancer	EPHA5 mutation	Non Small Cell Lung Cancer	atezolizumab Resistant: C3 – Early Trials BMC Pulm Med - 1 week (New C3) atezolizumab Resistant : C3 BMC Pulm Med - 1wk	atezolizumab Resistant: C3 – Early Trials BMC Pulm Med - 1 week atezolizumab Resistant : C3 BMC Pulm Med - 1 week - (New C3)
ARID1A mutation	Colorectal Cancer	ARID1A mutation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials Nat Commun - 1 week (New C3) cetuximab Resistant : C3 Nat Commun - 1wk	cetuximab Resistant: C3 – Early Trials Nat Commun - 1 week cetuximab Resistant : C3 Nat Commun - 1 week - (New C3)
ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	lorlatinib Resistant: C3 – Early Trials Curr Oncol - 1 week (New C4) lorlatinib Resistant : C3 Curr Oncol - 1wk	lorlatinib Resistant: C3 – Early Trials Curr Oncol - 1 week lorlatinib Resistant : C3 Curr Oncol - 1 week - (New C4)
BRAF V600E	Hairy Cell Leukemia	BRAF V600E	Hairy Cell Leukemia	trametinib + dabrafenib Sensitive: C3 – Early Trials Blood - 1 week (New C3) trametinib + dabrafenib Sensitive : C3 Blood - 1wk	trametinib + dabrafenib Sensitive: C3 – Early Trials Blood - 1 week trametinib + dabrafenib Sensitive : C3 Blood - 1 week - (New C3)
CCDC85A-ALK fusion	Lung Adenocarcinoma	CCDC85A-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 1 week (New C4) alectinib Sensitive : C4 J Cell Mol Med - 1wk	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 1 week alectinib Sensitive : C4 J Cell Mol Med - 1 week - (New C4)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MAM-06.301 Sensitive: D – Preclinical Cancer Cell Int - 1 week (New D) MAM-06.301 Sensitive : D Cancer Cell Int - 1wk	MAM-06.301 Sensitive: D – Preclinical Cancer Cell Int - 1 week MAM-06.301 Sensitive : D Cancer Cell Int - 1 week - (New D)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 2 weeks (New B) pembrolizumab Sensitive : A1 Lancet Oncol - 2wk	pembrolizumab Sensitive: A1 - Approval Lancet Oncol - 2 weeks pembrolizumab Sensitive : A1 Lancet Oncol - 2 weeks - (New B)
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide capsule Sensitive: A1 - Approval FDA - 2 weeks (New A1) enzalutamide capsule Sensitive : A1 FDA - 2wk	enzalutamide capsule Sensitive: A1 - Approval FDA - 2 weeks enzalutamide capsule Sensitive : A1 FDA - 2 weeks - (New A1)
FOLR1 overexpression	Ovarian Cancer	FOLR1 overexpression	Ovarian Cancer	IMGN 853 Sensitive: B - Late Trials IGCS 2022 - 2 weeks (New C3) IMGN 853 Sensitive : B IGCS 2022 - 2wk	IMGN 853 Sensitive: B - Late Trials IGCS 2022 - 2 weeks IMGN 853 Sensitive : B IGCS 2022 - 2 weeks - (New C3)
FOLR1 expression	Ovarian Cancer	FOLR1 expression	Ovarian Cancer	IMGN 853 Sensitive: B - Late Trials IGCS 2022 - 2 weeks (New C3) IMGN 853 Sensitive : B IGCS 2022 - 2wk	IMGN 853 Sensitive: B - Late Trials IGCS 2022 - 2 weeks IMGN 853 Sensitive : B IGCS 2022 - 2 weeks - (New C3)
No biomarker	T Cell Non-Hodgkin Lymphoma	No biomarker	T Cell Non-Hodgkin Lymphoma	sugemalimab Sensitive: B - Late Trials CStone Pharma Press Release - 2 weeks (New B) sugemalimab Sensitive : B CStone Pharma Press Release - 2wk	sugemalimab Sensitive: B - Late Trials CStone Pharma Press Release - 2 weeks sugemalimab Sensitive : B CStone Pharma Press Release - 2 weeks - (New B)
No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks (New B) XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2wk	XMT-1660 Sensitive: B - Late Trials Mersana Therapeutics Press Release - 2 weeks XMT-1660 Sensitive : B Mersana Therapeutics Press Release - 2 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval Breast Cancer Res Treat - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : A1 Breast Cancer Res Treat - 2wk	trastuzumab + pertuzumab Sensitive: A1 - Approval Breast Cancer Res Treat - 2 weeks trastuzumab + pertuzumab Sensitive : A1 Breast Cancer Res Treat - 2 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A1 - Approval Front Oncol - 2 weeks (New C3) pembrolizumab Sensitive : A1 Front Oncol - 2wk	pembrolizumab Sensitive: A1 - Approval Front Oncol - 2 weeks pembrolizumab Sensitive : A1 Front Oncol - 2 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Clin Cancer Res - 2 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 Clin Cancer Res - 2wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval Clin Cancer Res - 2 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 Clin Cancer Res - 2 weeks - (New C3)
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	crizotinib Sensitive: A1 - Approval JTO Clin Res Rep - 2 weeks (New C3) crizotinib Sensitive : A1 JTO Clin Res Rep - 2wk	crizotinib Sensitive: A1 - Approval JTO Clin Res Rep - 2 weeks crizotinib Sensitive : A1 JTO Clin Res Rep - 2 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	savolitinib Sensitive: A1 - Approval Front Oncol - 2 weeks (New C4) savolitinib Sensitive : A1 Front Oncol - 2wk	savolitinib Sensitive: A1 - Approval Front Oncol - 2 weeks savolitinib Sensitive : A1 Front Oncol - 2 weeks - (New C4)
FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval Canada Newswire - 2 weeks (New A1) lutetium Lu 177 vipivotide tetraxetan Sensitive : A1 Canada Newswire - 2wk	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval Canada Newswire - 2 weeks lutetium Lu 177 vipivotide tetraxetan Sensitive : A1 Canada Newswire - 2 weeks - (New A1)
HER-2 underexpression	HER2 Positive Breast Cancer	HER-2 underexpression	HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials Clin Cancer Res - 2 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : B Clin Cancer Res - 2wk	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials Clin Cancer Res - 2 weeks fam-trastuzumab deruxtecan-nxki Sensitive : B Clin Cancer Res - 2 weeks - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C4) BAY 1895344 Sensitive : C3 IGCS 2022 - 2wk	BAY 1895344 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks BAY 1895344 Sensitive : C3 IGCS 2022 - 2 weeks - (New C4)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
DDR	Ovarian Cancer	DDR	Ovarian Cancer	BAY 1895344 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) BAY 1895344 Sensitive : C3 IGCS 2022 - 2wk	BAY 1895344 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks BAY 1895344 Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	MSI-H/dMMR + MLH1 deletion	Endometrial Cancer	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) dostarlimab Sensitive : C3 IGCS 2022 - 2wk	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks dostarlimab Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
FOLR1 positive	Ovarian Cancer	FOLR1 positive	Ovarian Cancer	bevacizumab + IMGN 853 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) bevacizumab + IMGN 853 Sensitive : C3 IGCS 2022 - 2wk	bevacizumab + IMGN 853 Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks bevacizumab + IMGN 853 Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
MSH2 deletion + MSH6 deletion	Endometrial Cancer	MSH2 deletion + MSH6 deletion	Endometrial Cancer	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) dostarlimab Sensitive : C3 IGCS 2022 - 2wk	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks dostarlimab Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
MLH1 deletion+ PMS2 deletion	Endometrial Cancer	MLH1 deletion+ PMS2 deletion	Endometrial Cancer	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks (New C3) dostarlimab Sensitive : C3 IGCS 2022 - 2wk	dostarlimab Sensitive: C3 – Early Trials IGCS 2022 - 2 weeks dostarlimab Sensitive : C3 IGCS 2022 - 2 weeks - (New C3)
ALK rearrangement + PD-L1 overepxression	Non Small Cell Lung Cancer	ALK rearrangement + PD-L1 overepxression	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks (New C3) ALK inhibitor Resistant : C3 Front Immunol - 2wk	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks ALK inhibitor Resistant : C3 Front Immunol - 2 weeks - (New C3)
ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK rearrangement + CTLA4 overexpression	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks (New C3) ALK inhibitor Resistant : C3 Front Immunol - 2wk	ALK inhibitor Resistant: C3 – Early Trials Front Immunol - 2 weeks ALK inhibitor Resistant : C3 Front Immunol - 2 weeks - (New C3)
NEK2 overexpression + Chr t(4;14)	Multiple Myeloma	NEK2 overexpression + Chr t(4;14)	Multiple Myeloma	bortezomib Resistant: C3 – Early Trials J Clin Pharm Ther - 2 weeks (New C3) bortezomib Resistant : C3 J Clin Pharm Ther - 2wk	bortezomib Resistant: C3 – Early Trials J Clin Pharm Ther - 2 weeks bortezomib Resistant : C3 J Clin Pharm Ther - 2 weeks - (New C3)
CPEB1 underexpression	Gastric Adenocarcinoma	CPEB1 underexpression	Gastric Adenocarcinoma	5-fluorouracil Sensitive: C3 – Early Trials J Gastrointest Oncol - 2 weeks (New C3) 5-fluorouracil Sensitive : C3 J Gastrointest Oncol - 2wk	5-fluorouracil Sensitive: C3 – Early Trials J Gastrointest Oncol - 2 weeks 5-fluorouracil Sensitive : C3 J Gastrointest Oncol - 2 weeks - (New C3)
SPOP mutation	Prostate Cancer	SPOP mutation	Prostate Cancer	Androgen receptor inhibitor Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks (New C3) Androgen receptor inhibitor Sensitive : C3 Clin Cancer Res - 2wk	Androgen receptor inhibitor Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks Androgen receptor inhibitor Sensitive : C3 Clin Cancer Res - 2 weeks - (New C3)
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks (New C3) atezolizumab Sensitive : C3 Nat Med - 2wk	atezolizumab Sensitive: C3 – Early Trials Nat Med - 2 weeks atezolizumab Sensitive : C3 Nat Med - 2 weeks - (New C3)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks (New C4) pembrolizumab Sensitive : C4 Lung Cancer - 2wk	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks pembrolizumab Sensitive : C4 Lung Cancer - 2 weeks - (New C4)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks (New C4) afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2wk	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2 weeks - (New C4)
CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDK6 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks (New D) CDK6 inhibitor Resistant : D Nat Commun - 2wk	CDK6 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks CDK6 inhibitor Resistant : D Nat Commun - 2 weeks - (New D)
CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDKN2A overexpression	Estrogen Receptor Positive Breast Cancer	CDK4 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks (New D) CDK4 inhibitor Resistant : D Nat Commun - 2wk	CDK4 inhibitor Resistant: D – Preclinical Nat Commun - 2 weeks CDK4 inhibitor Resistant : D Nat Commun - 2 weeks - (New D)
HER-2 overexpression	Ovarian Cancer	HER-2 overexpression	Ovarian Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical IGCS 2022 - 2 weeks (New D) fam-trastuzumab deruxtecan-nxki Sensitive : D IGCS 2022 - 2wk	fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical IGCS 2022 - 2 weeks fam-trastuzumab deruxtecan-nxki Sensitive : D IGCS 2022 - 2 weeks - (New D)
ATRX mutation	Uterine Corpus Leiomyosarcoma	ATRX mutation	Uterine Corpus Leiomyosarcoma	BAY 1895344 Sensitive: D – Preclinical IGCS 2022 - 2 weeks (New D) BAY 1895344 Sensitive : D IGCS 2022 - 2wk	BAY 1895344 Sensitive: D – Preclinical IGCS 2022 - 2 weeks BAY 1895344 Sensitive : D IGCS 2022 - 2 weeks - (New D)
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	durvalumab Sensitive: A1 - Approval FDA - 3 weeks (New A1) durvalumab Sensitive : A1 FDA - 3wk	durvalumab Sensitive: A1 - Approval FDA - 3 weeks durvalumab Sensitive : A1 FDA - 3 weeks - (New A1)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A2 ESMO 2022 - 3wk	pembrolizumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks pembrolizumab Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New B) sacituzumab govitecan-hziy Sensitive : A2 ESMO 2022 - 3wk	sacituzumab govitecan-hziy Sensitive: A2 - Guideline ESMO 2022 - 3 weeks sacituzumab govitecan-hziy Sensitive : A2 ESMO 2022 - 3 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) trastuzumab + abemaciclib Sensitive : A2 ESMO 2022 - 3wk	trastuzumab + abemaciclib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks trastuzumab + abemaciclib Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	Immunotherapy Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : A2 ESMO 2022 - 3wk	Immunotherapy Sensitive: A2 - Guideline ESMO 2022 - 3 weeks Immunotherapy Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : B ESMO 2022 - 3wk	Immunotherapy Sensitive: B - Late Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : B ESMO 2022 - 3 weeks - (New C3)
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Resistant : B ESMO 2022 - 3wk	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Resistant : B ESMO 2022 - 3 weeks - (New B)
HLA-A2 positive	Non Small Cell Lung Cancer	HLA-A2 positive	Non Small Cell Lung Cancer	OSE 2101 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) OSE 2101 Sensitive : B ESMO 2022 - 3wk	OSE 2101 Sensitive: B - Late Trials ESMO 2022 - 3 weeks OSE 2101 Sensitive : B ESMO 2022 - 3 weeks - (New C3)
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3wk	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : A1 ESMO 2022 - 3wk	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks afatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	lorlatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New B) lorlatinib Sensitive : A1 ESMO 2022 - 3wk	lorlatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks lorlatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New B)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks (New C3) gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3wk	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : A1 ESMO 2022 - 3wk	afatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks afatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New B) sotorasib Sensitive : A1 ESMO 2022 - 3wk	sotorasib Sensitive: A1 - Approval ESMO 2022 - 3 weeks sotorasib Sensitive : A1 ESMO 2022 - 3 weeks - (New B)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : A1 ESMO 2022 - 3wk	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks dostarlimab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New B) brigatinib Sensitive : A1 ESMO 2022 - 3wk	brigatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks brigatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New B)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) tepotinib Sensitive : A1 ESMO 2022 - 3wk	tepotinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks tepotinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) osimertinib Sensitive : A1 ESMO 2022 - 3wk	osimertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks osimertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) capmatinib Sensitive : A1 ESMO 2022 - 3wk	capmatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks capmatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pralsetinib Sensitive : A1 ESMO 2022 - 3wk	pralsetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks pralsetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks (New C3) gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3wk	gefitinib Sensitive: A1 - Approval J Cancer Res Clin Oncol - 3 weeks gefitinib Sensitive : A1 J Cancer Res Clin Oncol - 3 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) mobocertinib Sensitive : A1 ESMO 2022 - 3wk	mobocertinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks mobocertinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) durvalumab Sensitive : A1 ESMO 2022 - 3wk	durvalumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks durvalumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pralsetinib Sensitive : A1 ESMO 2022 - 3wk	pralsetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks pralsetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) cetuximab + encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3wk	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks cetuximab + encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A1 ESMO 2022 - 3wk	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks pembrolizumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) selpercatinib Sensitive : A1 ESMO 2022 - 3wk	selpercatinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks selpercatinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A1 ESMO 2022 - 3wk	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks pembrolizumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : A1 ESMO 2022 - 3wk	olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) bevacizumab + olaparib Sensitive : A1 ESMO 2022 - 3wk	bevacizumab + olaparib Sensitive: A1 - Approval ESMO 2022 - 3 weeks bevacizumab + olaparib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : A1 ESMO 2022 - 3wk	dostarlimab Sensitive: A1 - Approval ESMO 2022 - 3 weeks dostarlimab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) larotrectinib Sensitive : A1 ESMO 2022 - 3wk	larotrectinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks larotrectinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) larotrectinib Sensitive : A1 ESMO 2022 - 3wk	larotrectinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks larotrectinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) amivantamab-vmjw Sensitive : A1 ESMO 2022 - 3wk	amivantamab-vmjw Sensitive: A1 - Approval ESMO 2022 - 3 weeks amivantamab-vmjw Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3wk	encorafenib + binimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks encorafenib + binimetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + cobimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) vemurafenib + cobimetinib Sensitive : A1 ESMO 2022 - 3wk	vemurafenib + cobimetinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks vemurafenib + cobimetinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) larotrectinib Sensitive : A1 ESMO 2022 - 3wk	larotrectinib Sensitive: A1 - Approval ESMO 2022 - 3 weeks larotrectinib Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A1 ESMO 2022 - 3wk	pembrolizumab Sensitive: A1 - Approval ESMO 2022 - 3 weeks pembrolizumab Sensitive : A1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	pembrolizumab Sensitive: A1 - Approval J Am Acad Dermatol - 3 weeks (New C3) pembrolizumab Sensitive : A1 J Am Acad Dermatol - 3wk	pembrolizumab Sensitive: A1 - Approval J Am Acad Dermatol - 3 weeks pembrolizumab Sensitive : A1 J Am Acad Dermatol - 3 weeks - (New C3)
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	alectinib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : A2 ESMO 2022 - 3wk	alectinib Sensitive: A2 - Guideline ESMO 2022 - 3 weeks alectinib Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression	Non Small Cell Lung Cancer	PD-L1 underexpression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New B) nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3 weeks - (New B)
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) pembrolizumab Sensitive : A2 ESMO 2022 - 3wk	pembrolizumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks pembrolizumab Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : A2 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) pyrotinib Sensitive : B ESMO 2022 - 3wk	pyrotinib Sensitive: B - Late Trials ESMO 2022 - 3 weeks pyrotinib Sensitive : B ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	pembrolizumab Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) pembrolizumab Sensitive : B ESMO 2022 - 3wk	pembrolizumab Sensitive: B - Late Trials ESMO 2022 - 3 weeks pembrolizumab Sensitive : B ESMO 2022 - 3 weeks - (New B)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) trastuzumab + pyrotinib Sensitive : B ESMO 2022 - 3wk	trastuzumab + pyrotinib Sensitive: B - Late Trials ESMO 2022 - 3 weeks trastuzumab + pyrotinib Sensitive : B ESMO 2022 - 3 weeks - (New B)
HRD	Ovarian Cancer	HRD	Ovarian Cancer	olaparib Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : B ESMO 2022 - 3wk	olaparib Sensitive: B - Late Trials ESMO 2022 - 3 weeks olaparib Sensitive : B ESMO 2022 - 3 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) dalpiciclib Sensitive : B ESMO 2022 - 3wk	dalpiciclib Sensitive: B - Late Trials ESMO 2022 - 3 weeks dalpiciclib Sensitive : B ESMO 2022 - 3 weeks - (New B)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) DZD9008 Sensitive : B ESMO 2022 - 3wk	DZD9008 Sensitive: B - Late Trials ESMO 2022 - 3 weeks DZD9008 Sensitive : B ESMO 2022 - 3 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	RAD1901 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) RAD1901 Sensitive : B ESMO 2022 - 3wk	RAD1901 Sensitive: B - Late Trials ESMO 2022 - 3 weeks RAD1901 Sensitive : B ESMO 2022 - 3 weeks - (New B)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3wk	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3 weeks - (New B)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New C3) cetuximab Sensitive : B ESMO 2022 - 3wk	cetuximab Sensitive: B - Late Trials ESMO 2022 - 3 weeks cetuximab Sensitive : B ESMO 2022 - 3 weeks - (New C3)
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3wk	durvalumab + CP-675206 Sensitive: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Sensitive : B ESMO 2022 - 3 weeks - (New B)
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	durvalumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) durvalumab Sensitive : C1 ESMO 2022 - 3wk	durvalumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks durvalumab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) trametinib + dabrafenib Sensitive : C1 ESMO 2022 - 3wk	trametinib + dabrafenib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks trametinib + dabrafenib Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	capmatinib Sensitive: C1 - Off-label Onco Targets Ther - 3 weeks (New C4) capmatinib Sensitive : C1 Onco Targets Ther - 3wk	capmatinib Sensitive: C1 - Off-label Onco Targets Ther - 3 weeks capmatinib Sensitive : C1 Onco Targets Ther - 3 weeks - (New C4)
MSI-H/dMMR	Gastrointestinal Cancer	MSI-H/dMMR	Gastrointestinal Cancer	dostarlimab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) dostarlimab Sensitive : C1 ESMO 2022 - 3wk	dostarlimab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks dostarlimab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C1 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C1 ESMO 2022 - 3wk	atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks atezolizumab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation	Solid Tumor	BRCA2 mutation	Solid Tumor	olaparib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : C1 ESMO 2022 - 3wk	olaparib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks olaparib Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Solid Tumor	BRCA1 mutation	Solid Tumor	olaparib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) olaparib Sensitive : C1 ESMO 2022 - 3wk	olaparib Sensitive: C1 - Off-label ESMO 2022 - 3 weeks olaparib Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) ARQ 087 Sensitive : C2 ESMO 2022 - 3wk	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks ARQ 087 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
BRAF mutation	Melanoma	BRAF mutation	Melanoma	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria Cancer Treat Rev - 3 weeks (New C3) encorafenib + binimetinib Sensitive : C2 Cancer Treat Rev - 3wk	encorafenib + binimetinib Sensitive: C2 – Inclusion Criteria Cancer Treat Rev - 3 weeks encorafenib + binimetinib Sensitive : C2 Cancer Treat Rev - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MRTX849 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) MRTX849 Sensitive : C2 ESMO 2022 - 3wk	MRTX849 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks MRTX849 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification	Cholangiocarcinoma	FGFR2 amplification	Cholangiocarcinoma	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) ARQ 087 Sensitive : C2 ESMO 2022 - 3wk	ARQ 087 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks ARQ 087 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) durvalumab Sensitive : C2 ESMO 2022 - 3wk	durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks durvalumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) bevacizumab + olaparib + durvalumab Sensitive : C2 ESMO 2022 - 3wk	bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks bevacizumab + olaparib + durvalumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) bevacizumab + olaparib + durvalumab Sensitive : C2 ESMO 2022 - 3wk	bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks bevacizumab + olaparib + durvalumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	imatinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) imatinib Sensitive : C2 ESMO 2022 - 3wk	imatinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks imatinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Cervical Cancer	HER-2 mutation	Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) neratinib Sensitive : C2 ESMO 2022 - 3wk	neratinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks neratinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) avelumab Sensitive : C2 ESMO 2022 - 3wk	avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks avelumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 overexpression	Non Small Cell Lung Cancer	HER-2 overexpression	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : C2 ESMO 2022 - 3wk	fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks fam-trastuzumab deruxtecan-nxki Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) anlotinib Sensitive : C2 ESMO 2022 - 3wk	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks anlotinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	rivoceranib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) rivoceranib Sensitive : C2 ESMO 2022 - 3wk	rivoceranib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks rivoceranib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) GDC-9545 Sensitive : C2 ESMO 2022 - 3wk	GDC-9545 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks GDC-9545 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) cetuximab + avelumab Sensitive : C2 ESMO 2022 - 3wk	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks cetuximab + avelumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) anlotinib Sensitive : C2 ESMO 2022 - 3wk	anlotinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks anlotinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) RG6330 Sensitive : C2 ESMO 2022 - 3wk	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks RG6330 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Lung Cancer	HER-2 mutation	Lung Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) trastuzumab + pertuzumab Sensitive : C2 ESMO 2022 - 3wk	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks trastuzumab + pertuzumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) RG6330 Sensitive : C2 ESMO 2022 - 3wk	RG6330 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks RG6330 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C2 ESMO 2022 - 3wk	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks REGN5093 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C2 ESMO 2022 - 3wk	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks REGN5093 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	BI 907828 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) BI 907828 Sensitive : C2 ESMO 2022 - 3wk	BI 907828 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks BI 907828 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MDM2 amplification	Solid Tumor	MDM2 amplification	Solid Tumor	BI 907828 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) BI 907828 Sensitive : C2 ESMO 2022 - 3wk	BI 907828 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks BI 907828 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
ESR1 mutation	HER2 Negative Breast Cancer	ESR1 mutation	HER2 Negative Breast Cancer	lasofoxifene Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) lasofoxifene Sensitive : C2 ESMO 2022 - 3wk	lasofoxifene Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks lasofoxifene Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	vemurafenib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) vemurafenib Sensitive : C2 ESMO 2022 - 3wk	vemurafenib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks vemurafenib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
HER-2 expression	HER2 Positive Breast Cancer	HER-2 expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ado-trastuzumab emtansine Sensitive : C3 ESMO 2022 - 3wk	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ado-trastuzumab emtansine Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HRD + BRCA2 mutation	Ovarian Cancer	HRD + BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + olaparib Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + olaparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + olaparib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HRD + BRCA1 mutation	Ovarian Cancer	HRD + BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + olaparib Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + olaparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + olaparib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 3wk	cetuximab + MRTX849 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cetuximab + MRTX849 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials Anticancer Drugs - 3 weeks (New C4) ado-trastuzumab emtansine Sensitive : C3 Anticancer Drugs - 3wk	ado-trastuzumab emtansine Sensitive: C3 – Early Trials Anticancer Drugs - 3 weeks ado-trastuzumab emtansine Sensitive : C3 Anticancer Drugs - 3 weeks - (New C4)
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) brigatinib Sensitive : C3 ESMO 2022 - 3wk	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks brigatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 3wk	panitumumab + sotorasib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks panitumumab + sotorasib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + PCM-075 Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + PCM-075 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + PCM-075 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks (New C3) PD1 inhibitor Sensitive : C3 Cancers (Basel) - 3wk	PD1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks PD1 inhibitor Sensitive : C3 Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks (New C3) PD-L1 inhibitor Sensitive : C3 Cancers (Basel) - 3wk	PD-L1 inhibitor Sensitive: C3 – Early Trials Cancers (Basel) - 3 weeks PD-L1 inhibitor Sensitive : C3 Cancers (Basel) - 3 weeks - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab Resistant : C3 ESMO 2022 - 3wk	bevacizumab Resistant: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
ETV6-NTRK3 fusion	Salivary Gland Cancer	ETV6-NTRK3 fusion	Salivary Gland Cancer	larotrectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) larotrectinib Sensitive : C3 ESMO 2022 - 3wk	larotrectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks larotrectinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 + KN026 Sensitive : C3 ESMO 2022 - 3wk	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 + KN026 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 + KN026 Sensitive : C3 ESMO 2022 - 3wk	KN046 + KN026 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 + KN026 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trametinib + dabrafenib Sensitive : C3 ESMO 2022 - 3wk	trametinib + dabrafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trametinib + dabrafenib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 mutation	Non Small Cell Lung Cancer	EGFR exon 20 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : C3 ESMO 2022 - 3wk	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks afatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) sintilimab Sensitive : C3 BMC Cancer - 3wk	sintilimab Sensitive: C3 – Early Trials BMC Cancer - 3 weeks sintilimab Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
CREBBP mutation	Bladder Cancer	CREBBP mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + tepotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) osimertinib + tepotinib Sensitive : C3 ESMO 2022 - 3wk	osimertinib + tepotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks osimertinib + tepotinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RB1 wild-type	Small Cell Lung Cancer	RB1 wild-type	Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks (New C3) nivolumab Sensitive : C3 JCO Precis Oncol - 3wk	nivolumab Sensitive: C3 – Early Trials JCO Precis Oncol - 3 weeks nivolumab Sensitive : C3 JCO Precis Oncol - 3 weeks - (New C3)
BRAF V600	Pancreatic Cancer	BRAF V600	Pancreatic Cancer	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Glioma	BRAF V600	Glioma	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Thyroid Gland Anaplastic Carcinoma	BRAF V600	Thyroid Gland Anaplastic Carcinoma	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 amplification	Lung Cancer	HER-2 amplification	Lung Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + pertuzumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 Sensitive : C3 ESMO 2022 - 3wk	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KN046 Sensitive : C3 ESMO 2022 - 3wk	KN046 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KN046 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CEACAM5 overexpression	Gastric Cancer	CEACAM5 overexpression	Gastric Cancer	SAR408701 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) SAR408701 Sensitive : C3 ESMO 2022 - 3wk	SAR408701 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks SAR408701 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation + HR positive	HER2 Negative Breast Cancer	BRCA2 mutation + HR positive	HER2 Negative Breast Cancer	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) niraparib Sensitive : C3 ESMO 2022 - 3wk	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks niraparib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation + HR positive	HER2 Negative Breast Cancer	BRCA1 mutation + HR positive	HER2 Negative Breast Cancer	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) niraparib Sensitive : C3 ESMO 2022 - 3wk	niraparib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks niraparib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 amplification + KRAS exon 2 wild-type	Colorectal Cancer	HER-2 amplification + KRAS exon 2 wild-type	Colorectal Cancer	trastuzumab + lapatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + lapatinib Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + lapatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + lapatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BPI-7711 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) BPI-7711 Sensitive : C3 ESMO 2022 - 3wk	BPI-7711 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks BPI-7711 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PD1 inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) PD1 inhibitor Resistant : C3 ESMO 2022 - 3wk	PD1 inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks PD1 inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
PAK4 overexpression	Melanoma	PAK4 overexpression	Melanoma	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
PMS2 mutation	Melanoma	PMS2 mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
TERT mutation	Squamous Cell Carcinoma of Head and Neck	TERT mutation	Squamous Cell Carcinoma of Head and Neck	PD1 inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) PD1 inhibitor Sensitive : C3 ESMO 2022 - 3wk	PD1 inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks PD1 inhibitor Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KIT mutation	Melanoma	KIT mutation	Melanoma	imatinib + toripalimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) imatinib + toripalimab Sensitive : C3 ESMO 2022 - 3wk	imatinib + toripalimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks imatinib + toripalimab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CCDC6-RET fusion	Non Small Cell Lung Cancer	CCDC6-RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pralsetinib Sensitive : C3 ESMO 2022 - 3wk	pralsetinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pralsetinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALPP expression	Endometrial Cancer	ALPP expression	Endometrial Cancer	anti-ALPP CAR-T cells Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) anti-ALPP CAR-T cells Sensitive : C3 ESMO 2022 - 3wk	anti-ALPP CAR-T cells Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks anti-ALPP CAR-T cells Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALPP expression	Ovarian Cancer	ALPP expression	Ovarian Cancer	anti-ALPP CAR-T cells Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) anti-ALPP CAR-T cells Sensitive : C3 ESMO 2022 - 3wk	anti-ALPP CAR-T cells Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks anti-ALPP CAR-T cells Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HRAS Q61	Bladder Cancer	HRAS Q61	Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
TGFB1-L	Ovarian Cancer	TGFB1-L	Ovarian Cancer	CORT125134 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) CORT125134 Sensitive : C3 ESMO 2022 - 3wk	CORT125134 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks CORT125134 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
NR3C1 overexpression	Ovarian Cancer	NR3C1 overexpression	Ovarian Cancer	CORT125134 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) CORT125134 Sensitive : C3 ESMO 2022 - 3wk	CORT125134 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks CORT125134 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	MET exon 14 mutation + MET overexpression	Non Small Cell Lung Cancer	capmatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib Sensitive : C3 ESMO 2022 - 3wk	capmatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + ALK wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3wk	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	MET exon 14 mutation + EGFR wild-type	Non Small Cell Lung Cancer	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3wk	capmatinib + PDR001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks capmatinib + PDR001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 G778_P780dup	Non Small Cell Lung Cancer	HER-2 G778_P780dup	Non Small Cell Lung Cancer	poziotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) poziotinib Sensitive : C3 ESMO 2022 - 3wk	poziotinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks poziotinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KEAP1 mutation	Non Small Cell Lung Cancer	KEAP1 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + ramucirumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + ramucirumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RAS wild-type + BRAF wild-type	Colorectal Cancer	RAS wild-type + BRAF wild-type	Colorectal Cancer	nivolumab + ipilimumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab + regorafenib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + ipilimumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + ipilimumab + regorafenib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KIT mutation	Non Small Cell Lung Cancer	KIT mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) CKD-702 Sensitive : C3 ESMO 2022 - 3wk	CKD-702 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks CKD-702 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BRAF V600	Melanoma	BRAF V600	Melanoma	vorinostat Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) vorinostat Sensitive : C3 ESMO 2022 - 3wk	vorinostat Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks vorinostat Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK positive	Non Small Cell Lung Cancer	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) brigatinib Sensitive : C3 ESMO 2022 - 3wk	brigatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks brigatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : C3 ESMO 2022 - 3wk	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks alectinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD3G overexpression	Renal Cell Carcinoma	CD3G overexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KRAS inhibitor Resistant : C3 ESMO 2022 - 3wk	KRAS inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks KRAS inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) KRAS inhibitor Sensitive : C3 ESMO 2022 - 3wk	KRAS inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks KRAS inhibitor Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RET positive + SMARCA4 mutation	Non Small Cell Lung Cancer	RET positive + SMARCA4 mutation	Non Small Cell Lung Cancer	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) RET inhibitor Resistant : C3 ESMO 2022 - 3wk	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks RET inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
RET positive + KRAS G12V	Non Small Cell Lung Cancer	RET positive + KRAS G12V	Non Small Cell Lung Cancer	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) RET inhibitor Resistant : C3 ESMO 2022 - 3wk	RET inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks RET inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion + TP53 mutation	Non Small Cell Lung Cancer	EGFR exon 20 insertion + TP53 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
BONSAI high signature	Renal Cell Carcinoma	BONSAI high signature	Renal Cell Carcinoma	cabozantinib tablet Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cabozantinib tablet Sensitive : C3 ESMO 2022 - 3wk	cabozantinib tablet Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cabozantinib tablet Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
NCAM1 overexpression	Renal Cell Carcinoma	NCAM1 overexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MTOR overexpression	Renal Cell Carcinoma	MTOR overexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD4 underexpression	Renal Cell Carcinoma	CD4 underexpression	Renal Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
SPOP mutation	Prostate Cancer	SPOP mutation	Prostate Cancer	enzalutamide capsule + abiraterone acetate + apalutamide Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) enzalutamide capsule + abiraterone acetate + apalutamide Sensitive : C3 ESMO 2022 - 3wk	enzalutamide capsule + abiraterone acetate + apalutamide Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks enzalutamide capsule + abiraterone acetate + apalutamide Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
AR wild-type	Prostate Cancer	AR wild-type	Prostate Cancer	abiraterone acetate Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) abiraterone acetate Sensitive : C3 ESMO 2022 - 3wk	abiraterone acetate Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks abiraterone acetate Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
AR wild-type	Prostate Cancer	AR wild-type	Prostate Cancer	enzalutamide capsule Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) enzalutamide capsule Sensitive : C3 ESMO 2022 - 3wk	enzalutamide capsule Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks enzalutamide capsule Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
GemPred signature	Pancreatic Adenocarcinoma	GemPred signature	Pancreatic Adenocarcinoma	gemcitabine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) gemcitabine Sensitive : C3 ESMO 2022 - 3wk	gemcitabine Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks gemcitabine Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HRD signature	Pancreatic Cancer	HRD signature	Pancreatic Cancer	FOLFIRINOX Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FOLFIRINOX Sensitive : C3 ESMO 2022 - 3wk	FOLFIRINOX Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FOLFIRINOX Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression + CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD8 expression	Esophageal Squamous Cell Carcinoma	CD8 expression	Esophageal Squamous Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Esophageal Squamous Cell Carcinoma	PD-1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	nivolumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + regorafenib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + regorafenib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + regorafenib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + LAG3 overexpression	Gastric Cancer	ITGAM overexpression + LAG3 overexpression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	ITGAM overexpression + CTLA4 overexpression	Gastric Cancer	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastric Cancer	PD-1 expression	Gastric Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR expression + HER-2 expression	Gastric Cancer	EGFR expression + HER-2 expression	Gastric Cancer	ASLAN001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ASLAN001 Sensitive : C3 ESMO 2022 - 3wk	ASLAN001 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ASLAN001 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ER positive + PGR positive	Neuroendocrine Tumor	ER positive + PGR positive	Neuroendocrine Tumor	tamoxifen Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) tamoxifen Sensitive : C3 ESMO 2022 - 3wk	tamoxifen Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks tamoxifen Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET amplification + MET overexpression	Non Small Cell Lung Cancer	MET amplification + MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C3 ESMO 2022 - 3wk	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks REGN5093 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C3 ESMO 2022 - 3wk	REGN5093 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks REGN5093 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CYP4B1 expression	Lung Cancer	CYP4B1 expression	Lung Cancer	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Resistant : C3 ESMO 2022 - 3wk	Immunotherapy Resistant: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
CLEC3B overexpression	Non Small Cell Lung Cancer	CLEC3B overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) Immunotherapy Sensitive : C3 ESMO 2022 - 3wk	Immunotherapy Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks Immunotherapy Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
EGFR exon 18 mutation + EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation + EGFR exon 21 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) afatinib Sensitive : C3 ESMO 2022 - 3wk	afatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks afatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-1 expression	Gastroesophageal Junction Adenocarcinoma	PD-1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ESMO 2022 - 3wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + ipilimumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
IDH wild-type	Glioblastoma	IDH wild-type	Glioblastoma	bevacizumab + retifanlimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + retifanlimab Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + retifanlimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + retifanlimab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
Chr amplification(15)(q22.31)	Squamous Cell Carcinoma of Head and Neck	Chr amplification(15)(q22.31)	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil + docetaxel Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cisplatin + 5-fluorouracil + docetaxel Sensitive : C3 ESMO 2022 - 3wk	cisplatin + 5-fluorouracil + docetaxel Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cisplatin + 5-fluorouracil + docetaxel Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) MEDI5752 Sensitive : C3 ESMO 2022 - 3wk	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks MEDI5752 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HLA-A*02:01	Uveal Melanoma	HLA-A*02:01	Uveal Melanoma	ipilimumab + tebentafusp Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) ipilimumab + tebentafusp Sensitive : C3 ESMO 2022 - 3wk	ipilimumab + tebentafusp Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks ipilimumab + tebentafusp Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression	Esophageal Squamous Cell Carcinoma	SLFN11 expression	Esophageal Squamous Cell Carcinoma	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3wk	cisplatin + 5-fluorouracil Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cisplatin + 5-fluorouracil Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CDK4 amplification	Mucosal Melanoma	CDK4 amplification	Mucosal Melanoma	dalpiciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) dalpiciclib Sensitive : C3 ESMO 2022 - 3wk	dalpiciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks dalpiciclib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	trastuzumab + tucatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + tucatinib Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + tucatinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + tucatinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) trastuzumab + abemaciclib Sensitive : C3 ESMO 2022 - 3wk	trastuzumab + abemaciclib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks trastuzumab + abemaciclib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 negative	Cervical Cancer	PD-L1 negative	Cervical Cancer	pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + tirvalimogene teraplasmid Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + tirvalimogene teraplasmid Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
CD27 overexpression	Clear Cell Renal Cell Carcinoma	CD27 overexpression	Clear Cell Renal Cell Carcinoma	PD1 inhibitor Resistant: C3 – Early Trials Clin Cancer Res - 3 weeks (New C3) PD1 inhibitor Resistant : C3 Clin Cancer Res - 3wk	PD1 inhibitor Resistant: C3 – Early Trials Clin Cancer Res - 3 weeks PD1 inhibitor Resistant : C3 Clin Cancer Res - 3 weeks - (New C3)
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	crizotinib Resistant: C4 – Case Studies Exp Ther Med - 3 weeks (New C4) crizotinib Resistant : C4 Exp Ther Med - 3wk	crizotinib Resistant: C4 – Case Studies Exp Ther Med - 3 weeks crizotinib Resistant : C4 Exp Ther Med - 3 weeks - (New C4)
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	TAS-117 Sensitive: C4 – Case Studies ESMO 2022 - 3 weeks (New C4) TAS-117 Sensitive : C4 ESMO 2022 - 3wk	TAS-117 Sensitive: C4 – Case Studies ESMO 2022 - 3 weeks TAS-117 Sensitive : C4 ESMO 2022 - 3 weeks - (New C4)
IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	IDH1 R132C + PIK3CA E545K + IDH2 R172K	Cholangiocarcinoma	ivosidenib Resistant: C4 – Case Studies NPJ Precis Oncol - 3 weeks (New C4) ivosidenib Resistant : C4 NPJ Precis Oncol - 3wk	ivosidenib Resistant: C4 – Case Studies NPJ Precis Oncol - 3 weeks ivosidenib Resistant : C4 NPJ Precis Oncol - 3 weeks - (New C4)
FGFR2 M540_I541insMM	Cholangiocarcinoma	FGFR2 M540_I541insMM	Cholangiocarcinoma	pemigatinib Sensitive: C4 – Case Studies Target Oncol - 3 weeks (New C4) pemigatinib Sensitive : C4 Target Oncol - 3wk	pemigatinib Sensitive: C4 – Case Studies Target Oncol - 3 weeks pemigatinib Sensitive : C4 Target Oncol - 3 weeks - (New C4)
FGFR3-TACC3 fusion + FGFR3 V555M	Urothelial Cancer	FGFR3-TACC3 fusion + FGFR3 V555M	Urothelial Cancer	TYRA-300 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) TYRA-300 Sensitive : D ESMO 2022 - 3wk	TYRA-300 Sensitive: D – Preclinical ESMO 2022 - 3 weeks TYRA-300 Sensitive : D ESMO 2022 - 3 weeks - (New D)
KIT exon 13 mutation	Gastrointestinal Stromal Tumor	KIT exon 13 mutation	Gastrointestinal Stromal Tumor	M4205 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) M4205 Sensitive : D ESMO 2022 - 3wk	M4205 Sensitive: D – Preclinical ESMO 2022 - 3 weeks M4205 Sensitive : D ESMO 2022 - 3 weeks - (New D)
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	lazertinib + ABN401 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) lazertinib + ABN401 Sensitive : D ESMO 2022 - 3wk	lazertinib + ABN401 Sensitive: D – Preclinical ESMO 2022 - 3 weeks lazertinib + ABN401 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR exon 19 deletion	Non Small Cell Lung Cancer	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) JIN-A02 Sensitive : D ESMO 2022 - 3wk	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks JIN-A02 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks (New D) JIN-A02 Sensitive : D ESMO 2022 - 3wk	JIN-A02 Sensitive: D – Preclinical ESMO 2022 - 3 weeks JIN-A02 Sensitive : D ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	osimertinib Resistant: D – Preclinical ESMO 2022 - 3 weeks (New D) osimertinib Resistant : D ESMO 2022 - 3wk	osimertinib Resistant: D – Preclinical ESMO 2022 - 3 weeks osimertinib Resistant : D ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	EGFR mutation + CDCA3 underexpression	Non Small Cell Lung Cancer	erlotinib Resistant: D – Preclinical ESMO 2022 - 3 weeks (New D) erlotinib Resistant : D ESMO 2022 - 3wk	erlotinib Resistant: D – Preclinical ESMO 2022 - 3 weeks erlotinib Resistant : D ESMO 2022 - 3 weeks - (New D)
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1	zanubrutinib Sensitive: A1 - Approval zanubrutinib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1	pomalidomide + elotuzumab Sensitive: A1 - Approval pomalidomide + elotuzumab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1	lisocabtagene maraleucel Sensitive: A1 - Approval lisocabtagene maraleucel Sensitive : A1
CD20 positive	Chronic Lymphocytic Leukemia	CD20 positive	Chronic Lymphocytic Leukemia	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1	rituximab-abbs Sensitive: A1 - Approval rituximab-abbs Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1	alectinib Sensitive: A1 - Approval alectinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1	brigatinib Sensitive: A1 - Approval brigatinib Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
No biomarker	Mediastinal B Cell Lymphoma	No biomarker	Mediastinal B Cell Lymphoma	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1	axicabtagene ciloleucel Sensitive: A1 - Approval axicabtagene ciloleucel Sensitive : A1
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1	brexucabtagene autoleucel Sensitive: A1 - Approval brexucabtagene autoleucel Sensitive : A1
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1